Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300Â U/mL compared with glargine 100Â U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension)

Over 12 months' treatment, participants with type 1 diabetes receiving Gla-300 achieved sustained glycaemic control and experienced less nocturnal hypoglycaemia that was confirmed (<3.0 mmol/L [<54 mg/dL]) or severe compared with Gla-100, supporting the 6-month results.